MA27809A1 - Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase - Google Patents

Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase

Info

Publication number
MA27809A1
MA27809A1 MA28613A MA28613A MA27809A1 MA 27809 A1 MA27809 A1 MA 27809A1 MA 28613 A MA28613 A MA 28613A MA 28613 A MA28613 A MA 28613A MA 27809 A1 MA27809 A1 MA 27809A1
Authority
MA
Morocco
Prior art keywords
phosphorylase
glycogen
pyrrolopyridine
carboxylic acid
acid amides
Prior art date
Application number
MA28613A
Other languages
English (en)
Inventor
Stuart Edward Bradley
Thomas Martin Krulle
Peter John Murray
Martin James Procter
Robert John Rowley
Smith Colin Peter Sambrook
Gerard Hugh Thomas
Karen Lesley Schofield
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA27809A1 publication Critical patent/MA27809A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogène-phosphorylase Les composés représentés par la formule (I) : ou leurs sels pharmaceutiquement acceptables, sont des inhibiteurs de la glycogène-phosphorylase et sont utiles dans le traitement prophylactique ou thérapeutique du diabète, de l'hyperglycémie, de l'hypercholestérolémie, de l??hyperinsulinémie, de l'hyperlipidémie, de l'hypertension, de l'athérosclérose ou d'une ischémie tissulaire, par exemple de l'ischémie myocardique, et comme cardioprotecteurs.
MA28613A 2003-05-21 2005-11-21 Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase MA27809A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US55125604P 2004-03-08 2004-03-08

Publications (1)

Publication Number Publication Date
MA27809A1 true MA27809A1 (fr) 2006-03-01

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28613A MA27809A1 (fr) 2003-05-21 2005-11-21 Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase

Country Status (16)

Country Link
EP (1) EP1636224B1 (fr)
JP (2) JP2006528702A (fr)
KR (1) KR101120935B1 (fr)
AT (1) ATE473974T1 (fr)
AU (1) AU2004240946B8 (fr)
BR (1) BRPI0410445B1 (fr)
CA (1) CA2525502C (fr)
DE (1) DE602004028122D1 (fr)
EA (1) EA009215B1 (fr)
IL (1) IL171851A (fr)
MA (1) MA27809A1 (fr)
MX (1) MXPA05012547A (fr)
NO (1) NO332265B1 (fr)
NZ (1) NZ543482A (fr)
UA (1) UA84146C2 (fr)
WO (1) WO2004104001A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
CA2545644C (fr) * 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Agonistes du recepteur de la melanocortine
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
JP2007531744A (ja) * 2004-04-05 2007-11-08 武田薬品工業株式会社 ６−アザインドール化合物
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
PL1819704T3 (pl) 2004-12-02 2008-12-31 Prosidion Ltd Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej
WO2006059163A1 (fr) * 2004-12-02 2006-06-08 Prosidion Limited Traitement du diabete par des inhibiteurs de la glycogene phosphorylase
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
EP1948597A1 (fr) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derives modulant des canaux ioniques
JP2009519293A (ja) * 2005-12-16 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３レセプター調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2089023A2 (fr) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Méthodes de traitement de la douleur neuroapathique au moyen d'agonistes de ppar-gamma
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
WO2012166389A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de néprilysine
CA2835220A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de neprilysine
US8513244B2 (en) 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
US9345247B2 (en) 2012-08-17 2016-05-24 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
JP7805583B2 (ja) * 2019-11-27 2026-01-26 国立研究開発法人理化学研究所 Ｇ９ａ阻害剤
EP4237423B1 (fr) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH 1h-pyrazolo[4,3-c]pyridines substitués et dérivés en tant qu'inhibiteurs de l'egfr
CA3211571A1 (fr) * 2021-03-10 2022-09-15 Donna L. Romero Inhibiteurs d'usp30 et leurs utilisations
WO2023165168A1 (fr) * 2022-10-27 2023-09-07 常州大学 APPLICATION D'UN DÉRIVÉ DE PYRAZOLE EN TANT QUE MODULATEUR, ANTAGONISTE ET AGONISTE ALLOSTÉRIQUE DU RÉCEPTEUR ADRÉNERGIQUE β2
CN115745891B (zh) * 2022-11-10 2025-08-01 常州大学 吡唑衍生物在作为β2-肾上腺素受体拮抗剂的应用
CN115894373B (zh) * 2022-10-27 2025-08-01 常州大学 N-取代苄基吡唑衍生物在作为β2肾上腺素受体调节剂、拮抗剂和激动剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
US5635527A (en) * 1994-06-06 1997-06-03 The Green Cross Corporation Carboxylic acid compound having condensed ring, salt thereof and pharmaceutical use thereof
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
FI974437A0 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina
KR100241643B1 (ko) * 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
BR0315681A (pt) * 2002-10-30 2005-09-06 Merck Frosst Canada Inc Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável

Also Published As

Publication number Publication date
JP5669691B2 (ja) 2015-02-12
WO2004104001A2 (fr) 2004-12-02
JP2011252005A (ja) 2011-12-15
IL171851A (en) 2011-08-31
WO2004104001A3 (fr) 2005-03-03
NO20055305D0 (no) 2005-11-10
UA84146C2 (ru) 2008-09-25
NZ543482A (en) 2009-02-28
NO20055305L (no) 2005-12-15
EA009215B1 (ru) 2007-12-28
AU2004240946A1 (en) 2004-12-02
BRPI0410445B1 (pt) 2017-11-28
CA2525502C (fr) 2012-12-18
ATE473974T1 (de) 2010-07-15
CA2525502A1 (fr) 2004-12-02
EP1636224A2 (fr) 2006-03-22
MXPA05012547A (es) 2006-05-25
JP2006528702A (ja) 2006-12-21
AU2004240946B8 (en) 2012-01-12
EA200501645A1 (ru) 2006-06-30
AU2004240946B2 (en) 2011-09-08
KR20060069792A (ko) 2006-06-22
KR101120935B1 (ko) 2012-03-05
NO332265B1 (no) 2012-08-13
BRPI0410445A (pt) 2006-05-30
DE602004028122D1 (de) 2010-08-26
EP1636224B1 (fr) 2010-07-14

Similar Documents

Publication Publication Date Title
BRPI0410445A (pt) inibidores de amida de ácido pirrolopiridina-2-carboxìlico de glicogênio fosforilase
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
BG100635A (bg) Заместени n-(индол-2-карбонил)-бета-аланинамиди и техни производни като антидиабетични средства
JO2282B1 (en) Oxazole derivatives
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
ATE384058T1 (de) Thiazolderivate
CA2481723A1 (fr) Modulateurs du recepteur 5ht<sb>2c</sb>
DE60219954D1 (de) Neue Indol-2-on Derivate
AUPR213700A0 (en) Antiviral agents
EP2168962A3 (fr) Phénylacétamides et leur utilisation en tant que modulateurs de la glucokinase
EP1088824A3 (fr) Amides de pyrrole bicycliques comme inhibiteurs du glycogène phosphorylase
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EE200300083A (et) Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
ATE483708T1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
PT992509E (pt) Novos derivados macrolidos
MXPA04006041A (es) Antivirales de piridoquinoxalina.
BR0212899A (pt) Compostos orgânicos
AU2566101A (en) Compounds and methods for the treatment of pain
PT1280527E (pt) Utilizacao de derivados de acriloil distamicina no tratamento de tumores associados a niveis de glutationa elevados
WO2005085194A3 (fr) Hydrazides d'acide indole-2-carboxylique
TW200509941A (en) Pharmaceutical solution composition
WO2006004903A3 (fr) 1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant